Exelixis Sees 10.1% Growth Forecast with A-Grade VGM Score
Exelixis holds a Zacks Rank #3 (Hold) with A-grade VGM and Growth Scores, forecasting 10.1% year-over-year earnings growth for fiscal 2026. Six analysts raised the consensus EPS estimate by $0.21 to $3.39, reflecting a 25% average earnings surprise.
1. Zacks Rank and Style Scores
Exelixis is currently rated #3 (Hold) on the Zacks Rank scale and boasts A-grade ratings in both the VGM Score and Growth Style Score, highlighting a balanced combination of value, growth, and momentum factors.
2. Earnings Forecast and Analyst Revisions
The company’s Growth Score projects 10.1% year-over-year earnings growth for fiscal 2026, while six analysts have boosted the consensus EPS estimate by $0.21 to $3.39, and past results show an average earnings surprise of +25%.
3. Oncology Pipeline and Strategic Focus
Based in Alameda, California, Exelixis specializes in oncology, advancing a pipeline of small molecules, antibody-drug conjugates and biotherapeutics across multiple hard-to-treat cancer indications through internal development and strategic partnerships.